KRAS and adenosquamous lung carcinoma: Fifty-seven adenosquamous lung carcinoma resected between October 2007 to January 2013 were analyzed for mutations in EGFR kinase domain, HER2 kinase domain, KRAS, BRAF, ALK, RET and AKT1. There were 20 (35.1%) EGFR mutations, 6 (10.5%) KRAS mutations, 1 (1.8%) HER2 mutation, 4 (7.0%) ALK fusions, 2 (3.5%) RET fusions and 2 (3.5%) AKT1 E17K mutations (Figure 2B).